EdiGene, Inc.

Clinical Roundup: Gene-Edited Therapies for Beta...
Jul. 26, 2023

In this roundup, we provide a summary of the ongoing gene-editing trials for beta thalassemia. This update includes trials sponsored by Vertex...

Clinical Update: EdiGene Enrols First Patient in...
Sep. 15, 2021

This week’s clinical update looks at a Phase 1 trial for ET-01, a CRISPR-edited blood cell therapy for beta thalassemia.

EdiGene, Inc.

Systemic Lupus Erythematosus, SLE, (NCT06373991)
Sponsors:
EdiGene Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-Cell Non-Hodgkin Lymphoma, NHL, (NCT06014073)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05752123)
Sponsors:
EdiGene (GuangZhou) Inc.
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, (NCT04933825)
Sponsors:
EdiGene Inc.
IND Enabling
Phase I
Phase II
Phase III
Transfusion-Dependent Beta-Thalassaemia, TDT, (NCT04925206)
Sponsors:
EdiGene (GuangZhou) Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion-Dependent Beta-Thalassemia, TDT, (NCT04390971)
Sponsors:
Institute of Hematology and Blood Diseases Hospital
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine